Filing Analysis
Spruce Biosciences, Inc. appointed Dr. Adrian Quartel as the new Chief Medical Officer, effective July 27, 2026. He replaces Interim CMO Dr. Kirk Ways, who will remain on the Company's Board of Directors.
📋 Key Facts
- Appointment date: July 27, 2026
- New Chief Medical Officer: Adrian Quartel, M.D., FFPM
- Outgoing Interim CMO: Dr. Kirk Ways (transitioning to Board member role)
- Dr. Quartel's background includes senior leadership roles at Zevra Therapeutics, Acer Therapeutics, Adamas Pharmaceuticals, and BioMarin Pharmaceutical.
Spruce Biosciences, Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected three Class III directors, ratified BDO USA, P.C. as the independent auditor for 2026, and approved executive compensation on an advisory basis.
🚩 Red Flags
- Significant shareholder opposition to director nominee Camilla V. Simpson, with approximately 36.2% of cast votes withheld (108,590 withheld vs 191,284 for).
- High level of shareholder dissent on executive compensation (Proposal 3), with approximately 37.3% of votes cast against the advisory measure (111,274 against vs 187,027 for).
📋 Key Facts
- The 2026 Annual Meeting of Stockholders was held on May 21, 2026, with 65.86% of outstanding shares represented.
- Michael Grey, Camilla V. Simpson, and Javier Szwarcberg were elected as Class III directors to serve until 2029.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders approved the advisory vote on executive compensation and favored an annual frequency for future executive compensation votes.
Spruce Biosciences announced its first quarter 2026 financial results and provided a corporate update. The company reported a preliminary cash and cash equivalents balance of $107.3 million as of April 30, 2026.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were released on May 13, 2026.
- Preliminary cash and cash equivalents totaled $107.3 million as of April 30, 2026.
- The cash estimate is unaudited and subject to final financial closing procedures.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
Spruce Biosciences entered into an underwriting agreement to raise approximately $69.0 million through a public offering of common stock and pre-funded warrants. The offering consists of 1,150,000 shares and 50,000 pre-funded warrants at a price of $50.00 per share, with underwriters already exercising their over-allotment option in full.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of up to 1,380,000 new shares (including over-allotment and warrant exercise).
📋 Key Facts
- Offering price set at $50.00 per share and $49.99 per pre-funded warrant.
- Gross proceeds are estimated at $69.0 million before underwriting discounts and expenses.
- Underwriters (Leerink Partners, Guggenheim Securities, and Oppenheimer & Co.) exercised their option to purchase an additional 180,000 shares in full on April 21, 2026.
- The offering is expected to close on April 22, 2026.
- Pre-funded warrants have an exercise price of $0.01 and include beneficial ownership limitations of 4.99% or 9.99%.
Spruce Biosciences and Kaken Pharmaceutical have mutually agreed to terminate their 2023 collaboration and license agreement for tildacerfont in Japan. The termination, effective March 31, 2026, results in the loss of up to $65 million in potential milestone payments and all future royalties from the Japanese market.
🚩 Red Flags
- Loss of a major strategic partner for the company's lead candidate in a key international market.
- Forfeiture of $65 million in potential non-dilutive milestone funding.
- The 'comprehensive assessment' language often masks disappointing clinical data or reduced commercial viability.
📋 Key Facts
- Termination Agreement signed on March 16, 2026, with an effective date of March 31, 2026.
- The original agreement (January 5, 2023) granted Kaken exclusive rights to develop and commercialize tildacerfont for congenital adrenal hyperplasia (CAH) in Japan.
- Kaken had previously made a non-refundable upfront payment of $15.0 million in April 2023.
- The Company forfeits approximately $65.0 million in aggregate milestone payments related to development, regulatory approval, and commercialization.
- The parties cited a 'comprehensive assessment of the tildacerfont program' as the reason for mutual termination.
- No early termination penalties were incurred by Spruce Biosciences.
Spruce Biosciences entered into a new at-the-market (ATM) sales agreement with Jefferies LLC and appointed Corwin Dale Hooks as Chief Commercial Officer. The company also reported its full-year 2025 financial results and terminated its prior 2022 sales agreement.
🚩 Red Flags
- Multiple 8-K items (1.01, 1.02, 2.02, 5.02) reported in a single filing.
- Establishment of a new ATM facility suggests an ongoing need for dilutive equity financing to fund operations.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on March 9, 2026, replacing a prior agreement from February 2022.
- The company may sell common stock through Jefferies with a commission of up to 3.0% of gross proceeds.
- Appointed Corwin Dale Hooks (age 60) as Chief Commercial Officer with an annual base salary of $480,000.
- Mr. Hooks received an inducement RSU award for 11,000 shares vesting over four years.
- Reported full-year 2025 financial results via press release on the same day.
Spruce Biosciences announced positive clinical data for its enzyme replacement therapy (TA-ERT) at the 22nd Annual WORLD Symposium. The data suggests TA-ERT stabilizes communication and motor skills in patients with Sanfilippo Syndrome Type B compared to natural history declines.
📋 Key Facts
- Presented data at the 22nd Annual WORLD Symposium regarding tralesinidase alfa enzyme replacement therapy (TA-ERT).
- Data from Observational Study 902 and Interventional Studies 250-201, 250-202, and 250-401 showed stabilization in receptive/expressive communication and motor skills.
- Treatment results were compared against natural history patients who showed decline in these outcomes.
- The company is seeking accelerated approval for TA-ERT based on existing clinical data.
Spruce Biosciences entered into a $50 million term loan agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P., featuring milestone-based funding tranches tied to regulatory progress of its TA-ERT therapy. The deal includes significant warrants for the lender and a substantial $6.4 million success fee in the event of a change of control.
🚩 Red Flags
- High interest rate floor (12.25%) suggests high risk profile for the lender.
- Significant 'Success Fee' ($6.4M) upon change of control acts as a heavy encumbrance on M&A activity.
- Milestone-contingent funding (Tranches 2, 3, and 4) creates significant liquidity uncertainty if regulatory/commercial targets are missed.
- Warrant exercise price tied to 'next bona fide round' can lead to significant dilution.
📋 Key Facts
- Total aggregate principal amount of up to $50.0 million via term loans.
- Tranche 1: $15.0 million funded within 5 business days after Jan 7, 2026.
- Tranche 2 & 3 ($20M total) are contingent upon achieving key regulatory milestones for TA-ERT (MPS IIIB).
- Discretionary Tranche 4: Up to $10.0 million subject to commercial milestones and lender approval.
- Interest rate is the greater of 12.25% or Prime + 5.25%.
- Lender receives a warrant for up to $3,200,000 worth of common stock with an exercise price at the lesser of $84.75 or the next equity financing price.
- A $6,400,000 'Success Fee' is payable to the lender if a change of control occurs before warrant issuance.
- Preliminary cash and cash equivalents as of Dec 31, 2025, were approximately $48.9 million.
Spruce Biosciences, Inc. announced the appointment of Keli Walbert to its Board of Directors and Compensation Committee, effective December 11, 2025.
📋 Key Facts
- Keli Walbert appointed as Class I Director, effective Dec 11, 2025.
- Appointed to the Compensation Committee of the Board.
- Granted nonstatutory stock options for 3,400 shares, vesting monthly over three years.
- Annual cash retainer: $40,000 for director service and $5,000 for Compensation Committee service (increasing to $5,500 for the committee in 2026).
- Term expires at the Company's 2027 Annual Meeting of Stockholders.
Spruce Biosciences announced the resignation of a board member and implemented a significant stock option repricing for key executives. The repricing targets 30,174 shares to address 'underwater' options, effectively lowering exercise prices to $104.13 per share.
🚩 Red Flags
- Significant option repricing for top executives (CEO and CFO) suggests previous equity incentives were deeply 'underwater' due to stock price decline.
- The original exercise prices ($344.25 and $1,506.00) are extremely high relative to the new price ($104.13), indicating massive loss in shareholder value since grant dates.
- Director departure (Tiba Aynechi) from both the Board and Compensation Committee.
📋 Key Facts
- Tiba Aynechi, Ph.D., resigned from the Board and as Chair of the Compensation Committee effective December 11, 2025.
- The company approved an option repricing on December 11, 2025, reducing exercise prices to $104.13 per share.
- Repricing applies to options with original exercise prices between $108.09 (calculated as 120% of the VWAP) and $1,506.00.
- Total shares subject to repricing: 30,174.
- CEO Javier Szwarcberg has 11,666 repriced options (original price $344.25).
- CFO Samir Gharib has 6,131 repriced options (original prices ranging from $122.65 to $1,506.00).
- Repriced options are subject to a retention period ending at the earliest of: 12 months from Dec 11, 2025; FDA approval of tralesinidase alfa; or a Change in Control.
Spruce Biosciences, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2025, and provided various corporate updates via a press release.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes financial results and corporate updates furnished in Exhibit 99.1.
- Company is an emerging growth company.
Spruce Biosciences, Inc. announced the resignation of Bali Muralidhar, Ph.D. from the Company's Board of Directors and its compensation committee, effective October 15, 2025.
🚩 Red Flags
- None identified; the filing contains standard 'no disagreement' language which typically mitigates concerns regarding director departures.
📋 Key Facts
- Bali Muralidhar, Ph.D. resigned as a director on October 15, 2025.
- The resignation includes his position on the Board's compensation committee.
- The departure is effective immediately.
- The Company explicitly states the resignation is not due to any disagreement regarding operations, policies, or practices.
Spruce Biosciences entered into a $50 million private placement agreement with institutional investors to issue common stock and pre-funded warrants. The capital is intended to support the development of its TA-ERT therapy, which has a projected BLA submission in Q1 2026.
🚩 Red Flags
- Pre-funded warrants are often used to avoid immediate dilution in certain contexts, but they represent significant future dilution when exercised.
- Requirement to register shares for resale within 20 days of closing carries cash penalties for registration failures.
📋 Key Facts
- Total expected gross proceeds: approximately $50.0 million.
- Securities issued: 502,181 shares of common stock and pre-funded warrants to purchase up to 233,144 shares.
- Pricing: $68.00 per share for common stock; $67.99 for pre-funded warrants (exercise price of $0.01).
- Expected closing date: On or about October 9, 2025.
- Placement agents include Leerink Partners, Citizens Capital Markets, and H.C. Wainwright & Co., with a combined fee of ~6.0%.
- The company must file registration statements for resale within 20 days after closing.
Spruce Biosciences, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025, and provided various corporate updates via a press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 14, 2025.
- The filing includes an earnings press release as Exhibit 99.1.
- Company is classified as an 'Emerging Growth Company'.
Spruce Biosciences, Inc. has announced a 1-for-75 reverse stock split effective August 4, 2025, following stockholder approval at the July 22, 2025 Annual Meeting. The move is intended to address Nasdaq compliance requirements regarding minimum bid price standards.
🚩 Red Flags
- Reverse stock split (typically a sign of extreme share price depression)
- Potential delisting risk: The filing notes trading may move to the OTC Pink Marketplace if the company fails to maintain the Nasdaq minimum bid price requirement for 20 consecutive days post-split.
📋 Key Facts
- Reverse stock split ratio: 1-for-75
- Effective date of the reverse split: August 4, 2025
- Trading on a split-adjusted basis expected to begin August 5, 2025
- New CUSIP number for common stock: 85209E 208
- Stockholders with fractional shares will receive cash payments in lieu of shares
- The company's common stock is scheduled to trade on the OTC Pink Marketplace if Nasdaq compliance is not maintained.
Spruce Biosciences has successfully appealed its Nasdaq delisting, allowing the company to resume trading on the Nasdaq Capital Market provided it regains compliance with the minimum bid price requirement by August 5, 2025. To achieve this, the company plans to seek stockholder approval for a reverse stock split (1-for-50 to 1-for-100) at its upcoming annual meeting on July 22, 2025.
🚩 Red Flags
- Delisting notice/failure to meet minimum bid price requirement.
- Proposed reverse stock split (1-for-50 to 1-for-100) is a significant red flag for micro-cap investors.
- Trading was already suspended and moved to OTC markets, indicating severe liquidity/valuation issues.
📋 Key Facts
- Company's common stock was suspended from Nasdaq and moved to OTC Pink Marketplace on April 29, 2025.
- Nasdaq Hearings Panel accepted the company's appeal on June 9, 2025.
- Trading is set to resume on Nasdaq Capital Market contingent upon regaining compliance by August 5, 2025.
- The Hearings Panel will maintain jurisdiction over the company until October 20, 2025.
- A reverse stock split with a ratio between 1-for-50 and 1-for-100 is being proposed to stockholders on July 22, 2025.
Spruce Biosciences issued a single share of Series A Preferred Stock to its Executive Chair, Michael Grey, which carries massive voting rights specifically tied to an upcoming Reverse Stock Split Proposal. This structure significantly alters the voting power required to approve a stock split and ensures the new preferred share mirrors common stock votes on that specific matter.
🚩 Red Flags
- Creation of a high-vote security (22,000,000 votes) specifically to facilitate/control a reverse stock split.
- The Series A Preferred is redeemable immediately upon the approval of a reverse split, suggesting it is a temporary vehicle for voting control.
- Significant dilution of voting power for existing common shareholders regarding corporate restructuring (reverse splits).
- Potential 'bridge' financing or control mechanism used by an insider to manage share count/price via a split.
📋 Key Facts
- On May 28, 2025, the Company issued one share of Series A Preferred Stock to Executive Chair Michael Grey for $100.00.
- The Series A Preferred Stock carries 22,000,000 votes, but these votes are restricted solely to 'Reverse Stock Split Proposals'.
- The Purchaser (Michael Grey) has agreed to vote the Series A share in proportion to how Common Stock is voted on a reverse split.
- Approval of a Reverse Stock Split now requires affirmative approval from a majority of both the Common Stock and the Series A Preferred Stock voting together as a single class.
- The Series A Preferred Stock is redeemable for $100.00 automatically immediately following the approval of a Reverse Stock Split Proposal.
Spruce Biosciences, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025 and provided various corporate updates.
🚩 Red Flags
- Trading status: The company is currently trading on the OTC Pink Marketplace rather than a major exchange, which often indicates lower liquidity and less stringent reporting requirements.
📋 Key Facts
- Reported financial results for Q1 ended March 31, 2025.
- The company's common stock began trading exclusively on the OTC Pink Marketplace on April 29, 2025 under the symbol 'SPRB'.
- The filing includes a press release (Exhibit 99.1) containing corporate updates.
Spruce Biosciences is facing imminent delisting from Nasdaq effective April 29, 2025, due to failure to meet the minimum bid price requirement. Simultaneously, the company has announced a massive 55% workforce reduction to prioritize its lead therapy development.
🚩 Red Flags
- Imminent delisting from a major exchange (Nasdaq).
- Massive 55% workforce reduction indicating severe cost-cutting/liquidity constraints.
- Planned reverse stock split to artificially inflate share price for compliance.
- Failure to regain compliance during the previously granted 180-day extension.
📋 Key Facts
- Nasdaq will suspend trading of SPRB on April 29, 2025, and move it to the over-the-counter (OTC) market.
- The company is implementing a 55% workforce reduction effective immediately, with termination dates by May 2, 2025.
- Estimated cash charges for the workforce reduction are approximately $0.9 million, primarily in severance and healthcare costs.
- The company plans to seek stockholder approval for a reverse stock split (ratio between 1-for-5 and 1-for-30) to regain Nasdaq compliance.
- An appeal has been filed with the Nasdaq Hearings Panel, but trading suspension will proceed regardless of the appeal.
Spruce Biosciences, Inc. issued a corporate update regarding a new strategic direction and the acquisition of tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B. The company reported a cash position of $38.8 million as of year-end 2024.
🚩 Red Flags
- Strategic pivots in micro-cap biotech often imply a shift away from previous pipeline candidates due to clinical or financial pressures.
📋 Key Facts
- Acquisition of tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B (MPSIIIB).
- Cash and cash equivalents balance was $38.8 million as of December 31, 2024.
- The company is pivoting to a new corporate strategy involving this specific therapeutic asset.
- Filing includes a press release (Exhibit 99.1) and a strategic presentation (Exhibit 99.2).
Spruce Biosciences, Inc. has filed a Form 12b-25 to notify the SEC of its inability to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
🚩 Red Flags
- Late filing of Annual Report (Form 10-K) is a common indicator of internal control weaknesses or accounting delays.
- Potential risk of non-compliance with exchange listing requirements if the delay is prolonged.
📋 Key Facts
- The company filed a Notification of Late Filing (Form 12b-25) on March 31, 2025.
- The delay pertains to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The filing includes certain estimates regarding results of operations and financial condition in Exhibit 99.1.
Spruce Biosciences announced the departure of its Chief Medical Officer, Ralph William Charlton III, effective December 31, 2024. Dr. Kirk Ways has been appointed as the interim Chief Medical Officer to fill the vacancy.
🚩 Red Flags
- Departure of a key executive (CMO) in the biopharmaceutical sector can disrupt clinical development timelines.
- Severance package includes significant cash outlay ($343,200).
📋 Key Facts
- Ralph William Charlton III, M.D., M.A.S, will cease employment on December 31, 2024.
- Dr. Charlton will receive a lump sum severance payment of $343,200 (equivalent to nine months of salary) and nine months of COBRA coverage.
- Kirk Ways, M.D., Ph.D., has been appointed interim Chief Medical Officer effective December 20, 2024.
- Dr. Ways brings significant industry experience from MBX Biosciences, Nuvelution Pharma, Janssen Pharmaceuticals, BioStratum, Aventis, and Lilly Research Laboratories.
Spruce Biosciences announced that its Phase 2b clinical trial (CAHmelia-204) failed to meet its primary efficacy endpoint for tildacerfont in treating Congenital Adrenal Hyperplasia. Consequently, the company is discontinuing both the CAHmelia-204 and CAHptain-205 studies and winding down its investment in tildacerfont.
🚩 Red Flags
- Failure of lead drug candidate (tildacerfont) to meet primary efficacy endpoint in Phase 2b trial.
- Discontinuation of clinical programs and winding down of core therapeutic investment.
- Announcement that the company is evaluating 'strategic options,' which often precedes restructuring, sale, or liquidation.
📋 Key Facts
- CAHmelia-204 (Phase 2b) failed to achieve primary efficacy endpoint: placebo-adjusted reduction in daily GC dose was only 0.7mg HCe (95% CI: -4.3 to 2.9, p=0.7).
- The company is discontinuing the CAHmelia-204 and CAHptain-205 clinical trials.
- Spruce Biosciences is winding down its investment in tildacerfont for the treatment of CAH.
- Management plans to evaluate a full range of strategic options regarding the company's future.
Spruce Biosciences, Inc. issued an 8-K to announce its financial results for the third quarter ended September 30, 2024, and provided various corporate updates.
📋 Key Facts
- Report date: November 11, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Spruce Biosciences received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. As part of this process, the company's listing is being transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement.
- Downgrade in listing tier (Global Select Market to Capital Market).
- Explicit mention of a potential reverse stock split to avoid delisting.
📋 Key Facts
- Nasdaq granted an extension until April 21, 2025, to meet the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- Effective October 28, 2024, common stock will be transferred from Nasdaq Global Select Market to Nasdaq Capital Market.
- Compliance can be achieved if the closing bid price is at least $1.00 for 10 consecutive business days.
- The company explicitly mentioned a reverse stock split as a potential option to regain compliance.
Spruce Biosciences, Inc. issued an 8-K to announce its financial results for the second quarter ended June 30, 2024, and provided various corporate updates.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Spruce Biosciences entered into a 'stalking horse' asset purchase agreement to acquire the rights to Avexitide from Eiger BioPharmaceuticals, which is currently in Chapter 11 bankruptcy. The company has also been designated as the back-up bidder following an auction process.
🚩 Red Flags
- Acquisition target (Eiger BioPharmaceuticals) is in Chapter 11 bankruptcy proceedings, introducing significant legal and procedural uncertainty.
- The final price for the assets could escalate significantly from the initial $10M to a net of $34.7M depending on auction outcomes.
📋 Key Facts
- Entered into a stalking horse asset purchase agreement on June 13, 2024, to acquire Avexitide assets from Eiger BioPharmaceuticals.
- Initial purchase price was set at $10.0 million, subject to adjustments and bankruptcy court approval.
- Following an auction on June 17, 2024, Spruce Biosciences was designated as the back-up bidder with a net purchase price of $34.7 million (after a $0.3 million termination fee credit).
- The acquisition is subject to Bankruptcy Court approval scheduled for June 26, 2024.
- If the winning bidder fails to close, Spruce Biosciences is obligated to consummate the acquisition as the back-up bidder.
Spruce Biosciences announced Phase 2 proof-of-concept results for its product candidate tildacerfont in treating Polycystic Ovary Syndrome (PCOS). The study showed significant reductions in DHEAS and increases in SHBG, suggesting therapeutic potential despite the trial not being powered for primary endpoint statistical significance.
🚩 Red Flags
- Trial was not powered to achieve statistical significance on the primary endpoint (DHEAS reduction).
📋 Key Facts
- Phase 2 POWER study evaluated tildacerfont (200 mg QD) vs. placebo in 27 female subjects with PCOS over 12 weeks.
- In patients with elevated baseline DHEAS, tildacerfont showed a significant reduction in DHEAS compared to placebo (p = 0.020).
- Tildacerfont demonstrated a significant increase in SHBG versus placebo (p = 0.012).
- The study reported that tildacerfont was well-tolerated with no serious adverse reactions or safety signals observed.
- The trial was not powered to test for statistical significance on the primary endpoint.
Spruce Biosciences held its 2024 Annual Meeting of Stockholders on May 22, 2024. The meeting resulted in the election of two Class I Directors and the ratification of BDO USA, LLP as the independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on May 22, 2024.
- Tiba Aynechi, Ph.D. and Kirk Ways, M.D., Ph.D. were elected as Class I Directors to serve until the 2027 Annual Meeting.
- BDO USA, LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- As of March 25, 2024, there were 41,152,616 shares outstanding entitled to vote.
Spruce Biosciences, Inc. issued an 8-K to announce its financial results for the first quarter ended March 31, 2024, and provided various corporate updates via a press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024
- Filing date: May 13, 2024
- The filing includes results of operations and financial condition under Item 2.02.
- Information provided is furnished rather than filed for purposes of Section 18 of the Exchange Act.
Spruce Biosciences, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock traded below $1.00 for 30 consecutive business days. The company has until October 23, 2024, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Stock price has been consistently below $1.00, indicating significant downward pressure or lack of market confidence.
- Risk of delisting if compliance is not met by October 23, 2024.
📋 Key Facts
- Received notice of non-compliance with Nasdaq Listing Rule 5450(a)(1) on April 26, 2024.
- The deficiency is due to the common stock minimum bid price being below $1.00 for 30 consecutive business days.
- The company has a 180-day grace period until October 23, 2024, to regain compliance by meeting the $1.00 threshold for at least 10 consecutive business days.
- Failure to comply within the initial period may allow for an additional 180-day extension if the company transfers to the Nasdaq Capital Market.
Spruce Biosciences announced a strategic realignment involving a 21% workforce reduction and the termination of its CAHmelia-203 clinical study after failing to meet its primary efficacy endpoint. While the pediatric study (CAHptain-205) showed promising preliminary data, the failure of the adult dose-response study necessitates significant cost-cutting and a shift in clinical strategy.
🚩 Red Flags
- Clinical trial failure (CAHmelia-203 failed primary efficacy endpoint).
- Significant workforce reduction (21% of staff).
- Termination of a clinical program as part of a 'Realignment Plan'.
- Uncertainty regarding future registrational program design pending Q3/Q4 results.
📋 Key Facts
- Termination of CAHmelia-203 study: Failed to achieve primary efficacy endpoint for A4 reduction (p-value was non-significant).
- Workforce Reduction: Approximately 21% of the workforce is being terminated, effective immediately.
- Study Termination: The Board approved a plan to terminate the CAHmelia-203 study as part of cost savings.
- Financial Impact: Estimated $0.4 million in cash charges related to severance and healthcare assistance, mostly expected in Q2 2024.
- CAHptain-205 Results: Preliminary data shows 73% of patients met the efficacy endpoint for A4 or glucocorticoid reduction at 12 weeks.
- Future Milestones: Topline results from CAHmelia-204 expected in Q3 2024; topline results from additional CAHptain-205 cohorts expected in Q4 2024.
Spruce Biosciences provided a corporate update regarding its clinical programs and reported preliminary cash and cash equivalents of approximately $96 million as of December 31, 2023. The company also released baseline patient characteristics for its Phase 2b CAHmelia clinical trials.
🚩 Red Flags
- Cash position is preliminary and subject to final financial closing procedures.
📋 Key Facts
- Estimated cash and cash equivalents as of Dec 31, 2023: ~$96 million (unaudited/preliminary).
- Phase 2b CAHmelia-203 trial enrollment: N=96 patients enrolled as of Dec 20, 2023.
- Phase 2b CAHmelia-204 trial enrollment: N=98 patients enrolled as of Dec 20, 2023.
- Final enrollment for both trials is anticipated to be completed in January 2024.
- Clinical focus: Tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).